NTRA

Natera
D

NTRA

153.310
USD
0.85
(0.56%)
مغلق
حجم التداول
55,414
الربح لكل سهم
-2
العائد الربحي
-
P/E
-104
حجم السوق
20,933,956,180
أصول ذات صلة
G
GH
0.910
(2.45%)
38.000 USD
HOLX
HOLX
-0.220
(-0.40%)
54.260 USD
ILMN
ILMN
-0.160
(-0.20%)
80.380 USD
M
MYGN
-0.01500
(-0.38%)
3.92000 USD
PODD
PODD
0.41
(0.13%)
321.44 USD
Q
QGEN
-0.275
(-0.65%)
42.050 USD
TMO
TMO
-6.77
(-1.69%)
393.52 USD
VEEV
VEEV
-2.506
(-1.06%)
232.990 USD
المزيد
الأخبار المقالات

العنوان: Natera

القطاع: Healthcare
الصناعة: Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.